Cerebral Venous Sinus Thrombosis in Women: Subgroup Analysis of the VENOST Study

Table 2

Comparison of etiological factors and outcome according to the RHRF (-) group or the RHRF (+) group.

Compared data	RHRF (-)		RHRF (+)
	%		%
Infections
Paracranial (focal) systemic	20	4	13	4	0.963
	7	2	5	2
History of VTE
Cerebral	11^a	2	2^a	0.6
Deep venous thrombosis	14^a	3	3^b	1	0.024
Other	6^a	1	2^a	0.6
Malignancy	32	7	1	0.3	<0.001
Family history VTE	5	1	1	0.3	0.409
MTHFR mutation
Heterozygote	19	7	9	4	0.120
Homozygote	24	8	9	4
Hyperhomocysteinemia	12	3	9	3	0.952
Prothrombin mutation	5	2	7	3	0.249
Protein C/S deficiency	25	7	13	5	0.302
Factor V Leiden mutation	11	4	11	5	0.405
Thrombocytosis	2	0.5	2	1	0.753
Polycythemia vera	3	1	0	0	0.267
Anticardiolipin Ab	2	0.5	1	0.4	0.752
PAI mutation	4	1	2	1	0.681
Antithrombin III deficiency	3	1	1	0.4	0.642
Hyperfibrinogenemia	0	0	2	1	0.178
Antiphospholipid Ab	7	2	4	2	0.767
Activated protein C	5	1	4	2	0.892
Resistance	13	4	4	2	0.114
High ANA titers
First month Rankin
0-1	304	80	236	81	0.276
2	40	11	37	13
>3	38	10	20	7
Third month Rankin
0-1	287	89	227	91
2	21	7	17	7	0.235
>3	15	5	5	2
Sixth month Rankin
0-1	262	90	215	96
2	16	6	6	3	0.061
>3	13	5	4	2
12th month Rankin
0-1	239	91	185	97
2	11	4	4	2	0.031
>3	13	5	2	1

ANA: antinuclear antibody; MTHFR: methylenetetrahydrofolate reductase; PAI: plasminogen activator inhibitor; VTE: venous thromboembolism.